Industry Forum Human Genetics

16–18 March 2022 | Würzburg

Organisational remarks

congress website

Main sponsors

Gold Sponsors


Agilent Technologies Sales & Services GmbH & Co. KG

Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life.
Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and
employs 16,400 people worldwide.

Information about Agilent is available at

To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Astra Zeneca GmbH

AstraZeneca´s focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, we hope to achieve life-changing benefits for patients.

AstraZeneca has a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world."

Silver Sponsors



Fluidigm develops, manufactures, and markets research products for life science analytical and preparatory systems for use in genomic applications. We sell to leading academic institutions, clinical research laboratories, pharmaceutical, and biotechnology companies worldwide. Our Biomark™ and the Juno™ systems are based on proprietary microfluidics which are designed to significantly simplify experimental workflow, increase throughput, and reduce costs of performing qPCR and NGS library preparation while providing excellent and reproducible data quality. 


Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise. With one of the largest sequencing capacities in the world, we utilise our deep scientific knowledge, first-class customer service and unsurpassed data quality to help clients realise their research goals in the rapidly evolving world of genomics.

With almost 2,000 employees, multiple locations around the world, 37 NGS related patents and over 670 publications in top tier journals such as Nature and Science, we have rapidly become a world-leader in NGS services.

Our Sequencing Centre on the Cambridge Science Park offers our customers an unrivalled NGS service with a quick turn-around, exceptional data quality and expert PhD level advice and support throughout your project. 


Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate sequencing platforms. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology. For more information, please visit and follow @PacBio.

Twist Bioscience
San Francisco, CA/US 

Bronze Sponsor

Takara Bio Europe SAS

Takara Bio Europe is a wholly owned subsidiary of Takara Bio Inc., who develops, manufactures, and distributes a wide range of life science reagents under the Takara™, Clontech®, and Cellartis® brands.

Key products include SMART cDNA synthesis kits for a variety of samples and applications, including NGS, high-performance qPCR and PCR reagents (including the Takara Ex Taq®, Takara LA Taq®, Titanium®, and Advantage® enzymes), Cellartis stem cells and stem cell reagents, RT enzymes and SMART library construction kits, the innovative In-Fusion® cloning system, Guide-it gene editing tools, Tet-based inducible gene expression systems, and Living Colors® fluorescent proteins.

Takara Bio’s portfolio supports applications including NGS, gene discovery, regulation, and function studies, as well as genetic analysis, protein expression and purification, gene editing, stem cell studies, and plant and food research. For more information, visit

PTC Therapeutics Germany GmbH
Frankfurt a.M./DE

PTC Therapeutics is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's mission is to provide access to best-in-class treatments for patients with an unmet medical need, using its ability to globally commercialize products as the foundation to drive investment in a robust and diversified pipeline of transformative medicines. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.

To learn more about PTC, please visit us at,  or


Nostos Genomics GmbH

Mehr als 300 Millionen Menschen weltweit sind von seltenen genetischen Krankheiten betroffen. Patienten, die unter solchen Krankheiten leiden, müssen häufig unzählige Arztbesuche, -überweisungen und Tests über sich ergehen lassen, um eine Diagnose zu erhalten. Genetische Tests wie die Exom-Sequenzierung können die Dauer und die Folgekosten dieser diagnostischen Odyssee verkürzen.

Die phänotypbasierte Interpretationsplattform ‘AION’ des Unternehmens Nostos Genomics ermöglicht es, die Komplexität der Varianteninterpretation deutlich zu verringern. Durch die patentierten Lernalgorithmen für Variantenklassifizierung und -priorisierung kann ‘AION’ Exom-Tests in weniger als 2 Minuten analysieren, während gleichzeitig die Anzahl der gelösten Fälle steigt. Modernste künstliche Intelligenz, kombiniert mit einer laufend aktualisierten Wissensdatenbank, übertrifft dabei die regelbasierte ACMG-Klassifikation um mehr als 50 % und liefert alle nötigen Informationen, um die Ergebnisse unabhängig verifizieren zu können.

‘AION’ unterstützt Labore somit dabei, große Teile ihrer Varianteninterpretation zu beschleunigen, sich auf komplexe Fälle zu konzentrieren und Geschäftsabläufe zu verbessern. Das Unternehmen bietet zudem eine API-Schnittstelle an, um ihre Lösung in bestehende Prozesse und Software nahtlos einzubinden. Die DSGVO-konforme und CE-IVD-zertifizierte Plattform wird bereits von namhaften Laboren in Deutschland und Europa genutzt. Nostos Genomics setzt zudem auf eine fortlaufende Verbesserung und Validierung, z. B. mithilfe von Daten des 100.000-Genome-Projekt aus Großbritannien.


Bionano Genomics, Inc.
San Diego/US

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Bionano transform the way the world sees the genome through Optical Genome Mapping solutions, diagnostic services, and software.

Bionano Genomics Saphyr® system for whole genome imaging offers an extremely long-read technology, providing unmatched sensitivity to detect structural variation, genome wide, at low cost. Different from sequencing and by leveraging direct visualization of DNA molecules, Bionano Saphyr’s workflow can resolve complex repetitive regions, identify Copy Number Variations, and elucidate genome-wide structural variation above 500 bp and at low allele fraction. Bionano’s high coverage depth allows for the detection of any type of structural variant (including balanced/unbalanced translocations, inversions, insertions, and deletions) with a 90% sensitivity, genome wide, and completely unbiased. 

Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data for visualization, interpretation and reporting of genomic data.

MCR Holland

MRC Holland produces assays for the detection of copy number variation (CNV). Their SALSA® MLPA® assays, that can detect up to 60 DNA targets in one assay, are the gold standard in the field of CNV determination. With the introduction of digitalMLPA™, MRC Holland is once again revolutionising the field of CNV detection by enabling the CNV determination of 1000 targets in one assay.

MRC Holland is a biotechnology company specialised in the production of assays for gene copy number and gene variant detection. MRC Holland is best known as the producer of MLPA® assays, which are used on millions of samples every year worldwide.

It is MRC Holland’s mission to manufacture and distribute affordable and reliable genetic tests worldwide. The company’s products are easy to use and implement into research and diagnostic settings, as they run on standard laboratory equipment, use standard platforms and free MRC Holland-developed software for analysis.

Genomic Vision